Cargando…

Clinical Experience with High-Dose Polymyxin B against Carbapenem-Resistant Gram-Negative Bacterial Infections—A Cohort Study

Population pharmacokinetic studies have suggested that high polymyxin B (PMB) doses (≥30,000 IU/kg/day) can improve bacterial kill in carbapenem-resistant Gram-negative bacteria (CR-GNB). We aim to describe the efficacy and nephrotoxicity of patients with CR-GNB infections prescribed high-dose PMB....

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Yiying, Leck, Hui, Tan, Ray W., Teo, Jocelyn Q., Lim, Tze-Peng, Lee, Winnie, Chlebicki, Maciej Piotr, Kwa, Andrea L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459528/ https://www.ncbi.nlm.nih.gov/pubmed/32726974 http://dx.doi.org/10.3390/antibiotics9080451

Ejemplares similares

Elimination of Extracellular Adenosine Triphosphate for the Rapid Prediction of Quantitative Plate Counts in 24 h Time-Kill Studies against Carbapenem-Resistant Gram-Negative Bacteria
por: Cai, Yiying, et al.
Publicado: (2020)

Carbapenem Resistance in Gram-Negative Bacteria: The Not-So-Little Problem in the Little Red Dot
por: Teo, Jocelyn Qi Min, et al.
Publicado: (2016)

Using an Adenosine Triphosphate Bioluminescent Assay to Determine Effective Antibiotic Combinations against Carbapenem-Resistant Gram Negative Bacteria within 24 Hours
por: Cai, Yiying, et al.
Publicado: (2015)

708. Incidence and Relatedness of Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Infections in Previously Colonized or Infected Patients
por: Tang, Sarah Si Lin, et al.
Publicado: (2018)

In-Vitro Activity of Polymyxin B, Rifampicin, Tigecycline Alone and in Combination against Carbapenem-Resistant Acinetobacter baumannii in Singapore
por: Lim, Tze-Peng, et al.
Publicado: (2011)

Efficacy and safety of polymyxin B in carbapenem-resistant gram-negative organisms infections
por: Xia, G. L., et al.
Publicado: (2021)

Effectiveness and Nephrotoxicity of Intravenous Polymyxin B in Carbapenem-Resistant Gram-Negative Bacterial Infections Among Chinese Children
por: Jia, Xuedong, et al.
Publicado: (2022)

Polymyxin B-Associated Nephrotoxicity and Its Predictors: A Retrospective Study in Carbapenem-Resistant Gram-Negative Bacterial Infections
por: Wu, Xiao-Li, et al.
Publicado: (2022)

Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug Resistant Acinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure
por: Zhou, Yvonne Peijun, et al.
Publicado: (2014)

Treatment and Outcomes of Infections Caused by Diverse Carbapenemase-Producing Carbapenem-Resistant Enterobacterales
por: Lim, Fang Kang, et al.
Publicado: (2020)

Low-dose polymyxin: an option for therapy of Gram-negative sepsis
por: Harm, Stephan, et al.
Publicado: (2016)

Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B
por: Lim, Tze-Peng, et al.
Publicado: (2011)

From Bench-Top to Bedside: A Prospective In Vitro Antibiotic Combination Testing (iACT) Service to Guide the Selection of Rationally Optimized Antimicrobial Combinations against Extensively Drug Resistant (XDR) Gram Negative Bacteria (GNB)
por: Cai, Yiying, et al.
Publicado: (2016)

Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study
por: Zhang, Xiaojuan, et al.
Publicado: (2021)

Evaluation of Ertapenem use with Impact Assessment on Extended-Spectrum Beta-Lactamases (ESBL) Production and Gram-Negative resistance in Singapore General Hospital (SGH)
por: Lim, Cheryl Li-Ling, et al.
Publicado: (2013)

Integrated pharmacokinetic–pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections
por: Lim, Tze-Peng, et al.
Publicado: (2018)

A Comparative Study of the Microbiological Efficacy of Polymyxin B on Different Carbapenem-Resistant Gram-Negative Bacteria Infections
por: Lu, Qiong, et al.
Publicado: (2021)

Risk Factors, Molecular Epidemiology and Outcomes of Ertapenem-Resistant, Carbapenem-Susceptible Enterobacteriaceae: A Case-Case-Control Study
por: Teo, Jocelyn, et al.
Publicado: (2012)

Performance of Population Pharmacokinetic Models in Predicting Polymyxin B Exposures
por: Tam, Vincent H., et al.
Publicado: (2020)

Predictors and Outcomes of Healthcare-Associated Infections Caused by Carbapenem-Nonsusceptible Enterobacterales: A Parallel Matched Case-Control Study
por: Hoo, Grace S. R., et al.
Publicado: (2022)

Novel Polymyxin Combination With Antineoplastic Mitotane Improved the Bacterial Killing Against Polymyxin-Resistant Multidrug-Resistant Gram-Negative Pathogens
por: Tran, Thien B., et al.
Publicado: (2018)

Treatment of Carbapenem-Resistant Multidrug-Resistant Gram-Negative Bacilli with Intracerebroventricular Injection of Polymyxin B: A Retrospective Study
por: Liu, Dongsheng, et al.
Publicado: (2022)

Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
por: Doi, Yohei
Publicado: (2019)

An area under the concentration–time curve threshold as a predictor of efficacy and nephrotoxicity for individualizing polymyxin B dosing in patients with carbapenem-resistant gram-negative bacteria
por: Yang, Jing, et al.
Publicado: (2022)

Polymyxin B-Based Regimens for Patients Infected with Carbapenem-Resistant Gram-Negative Bacteria: Clinical and Microbiological Efficacy, Mortality, and Safety
por: Qu, Jian, et al.
Publicado: (2022)

Coarse-grained simulations uncover Gram-negative bacterial defense against polymyxins by the outer membrane
por: Jiang, Xukai, et al.
Publicado: (2021)

Antimicrobial Peptides for Gram-Negative Sepsis: A Case for the Polymyxins
por: David, Sunil A.
Publicado: (2012)

Probing the Penetration of Antimicrobial Polymyxin Lipopeptides into Gram-Negative Bacteria
por: Deris, Zakuan Z., et al.
Publicado: (2014)

Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria
por: Bergen, Phillip J., et al.
Publicado: (2015)

Polymyxin Derivatives that Sensitize Gram-Negative Bacteria to Other Antibiotics
por: Vaara, Martti
Publicado: (2019)

Extensively drug-resistant Acinetobacter baumannii in a Thai hospital: a molecular epidemiologic analysis and identification of bactericidal Polymyxin B-based combinations
por: Teo, Jocelyn, et al.
Publicado: (2015)

Impact of Antimicrobial Stewardship Program (ASP) on Outcomes in Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) in an Acute-Tertiary Care Hospital
por: Loo, Li Wen, et al.
Publicado: (2015)

Efficacy and nephrotoxicity of polymyxin B in elderly patients with carbapenem resistant bacterial infection
por: Xia, G. L., et al.
Publicado: (2023)

Comparison of the clinical efficacy and toxicity of nebulized polymyxin monotherapy and combined intravenous and nebulized polymyxin for the treatment of ventilator-associated pneumonia caused by carbapenem-resistant gram-negative bacteria: a retrospective cohort study
por: Wu, Zhenping, et al.
Publicado: (2023)

An Observational Study on Early Empiric versus Culture-Directed Antifungal Therapy in Critically Ill with Intra-Abdominal Sepsis
por: Lee, Winnie, et al.
Publicado: (2014)

Bi-Functional Alginate Oligosaccharide–Polymyxin Conjugates for Improved Treatment of Multidrug-Resistant Gram-Negative Bacterial Infections
por: Stokniene, Joana, et al.
Publicado: (2020)

Candida Surveillance in Surgical Intensive Care Unit (SICU) in a Tertiary Institution
por: Liew, Yi Xin, et al.
Publicado: (2015)

Polymyxin E–Resistant Gram-Negative Bacteria in Tunisia and Neighboring Countries: Are There Commonalities?
por: Dziri, Olfa, et al.
Publicado: (2021)

Population Pharmacokinetics of Polymyxin B in Obese Patients for Resistant Gram-Negative Infections
por: Wang, Peile, et al.
Publicado: (2021)

In Vitro Susceptibility to Ceftazidime-Avibactam and Comparator Antimicrobial Agents of Carbapenem-Resistant Enterobacterales Isolates
por: Lim, Tze-Peng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_appjejcf42q23favaq4530qoce